1. Scrip
  2. >>Archive

Artecel Sciences Inc.

 
• By Jeff Dvorin

If recent studies are to be believed, America's obsession with diet and exercise has done little to trim the country's collective flab. While this is hardly good news on the health care front, one company is attempting to turn at least some of that fat into therapeutic muscle. In particular, Artecel Sciences Inc. is exploring ways in which cells harvested from fat tissue can be used in a variety of medical applications, including tissue repair and hematopoietic support for bone marrow transplantation.

If recent studies are to be believed, Americans' obsession with diet and exercise has done little to trim the country's collective flab; indeed the incidence of obesity appears to be steadily rising. While this is hardly good news on the health care front, one company is attempting to turn at least some of that fat into therapeutic muscle. In particular, Artecel Sciences Inc. is exploring ways in which cells harvested from fat tissue can be used in a variety of medical applications, including tissue repair and hematopoietic support for bone marrow transplantation.

Artecel, which is only a few months old, was spun off from Zen-Bio Inc. , a four year-old company that sells fat cells (adipocytes) to pharmaceutical and biotech companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.